In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 7_suppl ( 2017-03-01), p. 6-6
Abstract:
6 Background: We previously reported 16-gene pre- and 8-gene post-treatment response predictive gene signatures in whole blood that were trained in one cohort (N=210) of advanced melanoma patients treated with tremelimumab and validated in an independent test dataset (N=150) for both response and survival.(SITC 2016 Annual Meeting Poster Submission ID: 214348.) Methods: A correlation matrix was calculated for the change between pre- and post-treatment gene expression for all 169 genes in two independent clinical trials. The genes were ranked by their relationship with CTLA4. Comparison was made between the training and test datasets. Reliable biological signals exceeded technical variance of +/- 0.5 fold change. Results: Correlation of the change in gene expression relative to CTLA4 between the 169 genes in two independent datasets was consistent as to fold change and ranking. The literature describes the genes in the Table as playing a role in anti-CTLA4 and PD-1 immunotherapy. We found only ICOS to be predictive of gene response in our 16-gene pre- and 8-gene post-treatment algorithms. Conclusions: Several genes, such as CTLA4, CD28, CXCR3, IL32, FOXP3, CD25, CCR5, and IFNG, are consistently upregulated one to three fold from anti-CTLA4 immunotherapy but are not predictive of response. ClinicalTrials.gov NCT00257205. [Table: see text]
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2017.35.7_suppl.6
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2017
detail.hit.zdb_id:
2005181-5
Permalink